BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24

• Press Releases

  BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

  September 14, 2026

   · 

  12 min read
• Press Releases

  Johnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

  September 14, 2026

   · 

  15 min read
• Press Releases

  WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC

  September 14, 2026

   · 

  8 min read
• Press Releases

  Etienna Bio Completes FDA INTERACT Meeting for ETB-001

  September 14, 2026

   · 

  3 min read
• Press Releases

  FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara

  September 14, 2026

   · 

  12 min read
• Press Releases

  First Endometrial Cancer Awareness Week Launches in Canada

  September 14, 2026

   · 

  7 min read
• Press Releases

  Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

  September 14, 2026

   · 

  1 min read
• Press Releases

  Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

  September 14, 2026

   · 

  4 min read
• Press Releases

  Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

  September 14, 2026

   · 

  9 min read
• Press Releases

  Slate Medicines Appoints Kenneth Koblan, PhD, as Chief Scientific Officer

  September 14, 2026

   · 

  6 min read